ValuEngine downgraded shares of Ocular Therapeutix (NASDAQ:OCUL) from a sell rating to a strong sell rating in a report released on Friday, February 2nd.
Several other equities research analysts have also weighed in on OCUL. Zacks Investment Research upgraded Ocular Therapeutix from a sell rating to a hold rating in a research note on Saturday, November 11th. BTIG Research upgraded Ocular Therapeutix from a neutral rating to a buy rating in a research report on Friday, January 19th. HC Wainwright restated a buy rating and set a $10.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, November 8th. Finally, Guggenheim began coverage on Ocular Therapeutix in a research report on Monday, October 23rd. They set a buy rating and a $12.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $20.67.
Shares of Ocular Therapeutix (OCUL) opened at $4.91 on Friday. Ocular Therapeutix has a 12 month low of $3.30 and a 12 month high of $11.79. The firm has a market capitalization of $177.54, a P/E ratio of -2.16 and a beta of 1.53. The company has a quick ratio of 4.78, a current ratio of 4.79 and a debt-to-equity ratio of 0.39.
In other Ocular Therapeutix news, insider Antony C. Mattessich acquired 21,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 12th. The shares were acquired at an average price of $4.29 per share, with a total value of $90,090.00. Following the purchase, the insider now owns 21,000 shares of the company’s stock, valued at approximately $90,090. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Daniel M. Bollag acquired 24,700 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were acquired at an average cost of $3.93 per share, for a total transaction of $97,071.00. Following the purchase, the insider now directly owns 24,700 shares in the company, valued at approximately $97,071. The disclosure for this purchase can be found here. In the last three months, insiders bought 50,500 shares of company stock worth $206,361. 26.10% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the stock. Hikari Power Ltd acquired a new stake in Ocular Therapeutix during the 4th quarter worth $356,000. Northern Trust Corp increased its holdings in Ocular Therapeutix by 13.2% during the 2nd quarter. Northern Trust Corp now owns 262,139 shares of the biopharmaceutical company’s stock worth $2,430,000 after purchasing an additional 30,539 shares in the last quarter. State Street Corp increased its holdings in Ocular Therapeutix by 12.3% during the 2nd quarter. State Street Corp now owns 371,923 shares of the biopharmaceutical company’s stock worth $3,450,000 after purchasing an additional 40,782 shares in the last quarter. Jennison Associates LLC increased its holdings in Ocular Therapeutix by 1.0% during the 4th quarter. Jennison Associates LLC now owns 1,994,768 shares of the biopharmaceutical company’s stock worth $8,877,000 after purchasing an additional 20,132 shares in the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in Ocular Therapeutix by 97.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 60,519 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 29,937 shares in the last quarter. 37.08% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Ocular Therapeutix (NASDAQ:OCUL) Downgraded by ValuEngine to Strong Sell” was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/02/20/ocular-therapeutix-ocul-downgraded-by-valuengine-updated-updated.html.
About Ocular Therapeutix
Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.